Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Tizona Therapeutics, Inc
Essen Biotech
H. Lee Moffitt Cancer Center and Research Institute
Takeda
Novartis
Merck Sharp & Dohme LLC
University of Pittsburgh
Sichuan Baili Pharmaceutical Co., Ltd.
Coherus Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DEKA Biosciences
University of Colorado, Denver
Gustave Roussy, Cancer Campus, Grand Paris
Nimbus Therapeutics
Inhibrx Biosciences, Inc
Sumitomo Pharma America, Inc.
Celldex Therapeutics
Corvus Pharmaceuticals, Inc.
Kineta Inc.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Syndax Pharmaceuticals
University of California, Irvine